Compare Humana Inc (HUM) vs Tesla, Inc. (TSLA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Humana Inc vs Tesla, Inc. — how do they compare? Humana Inc trades at $403.52 (market cap $47.81B), while Tesla, Inc. trades at $379.76 (market cap $1.39T). The key difference: Tesla, Inc. is far larger — about 29.1× Humana Inc's market cap, and Humana Inc pays a 0.89% dividend while Tesla, Inc. pays none. Which is the better fit depends on your goals.
| HUM | TSLA | |
|---|---|---|
Market Cap | $47.81B | $1.39T |
Sector | Health | Consumer Cyclical |
52-Week High | $409.42 | $489.88 |
52-Week Low | $163.67 | $302.63 |
Enterprise Value | $56.85B | $1.36T |
Dividend Yield | 0.89% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Humana (HUM) trades at $398.09, down 0.48% with a bullish technical signal from moving averages. The company shows strong revenue growth to $129.66B in 2025 but faces margin compression with net income margin declining to 0.82%. Recent earnings have consistently beaten expectations, and analyst sentiment is mixed with 34% buy ratings but a consensus price target of $354.33 below current levels.
The outlook suggests cautious optimism with Medicare Advantage expansion opportunities but significant margin pressure and regulatory risks. Key investment considerations include the company's ability to achieve its 3% Medicare Advantage margin target by 2028 while navigating increased healthcare utilization costs and competitive pressures in the insurance sector.
Tesla (TSLA) trades at $375.25, down 1.47% amid a bearish technical signal and mixed earnings history. The stock faces pressure from declining profit margins (net income margin fell to 3.95% in 2025 from 15.49% in 2023) and elevated valuations (P/E of 339.06). Recent news highlights regulatory approval for driver-assistance software in Europe and a potential cheaper EV model, while analyst consensus remains divided with a $409.26 price target.
Tesla's outlook balances innovation in autonomy and energy against near-term execution risks and valuation concerns. Investment opportunities lie in its AI and robotics pivot, but risks include intense EV competition, margin compression, and reliance on future technology adoption. The stock's bearish technical trend and high P/E suggest cautious optimism is warranted.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Humana Inc
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →About Tesla, Inc.
Tesla Inc. designs, manufactures, and sells high-performance electric vehicles and electric vehicle powertrain components. The Company owns its sales and service network and sells electric power train components to other automobile manufacturers. Tesla serves customers worldwide.
Read more on TSLA →
